2009 SIPREC consensus document executive summary: Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance

被引：0

作者：

Volpe M. ^{[1
,2
]}

Borghi C. ^{[3
]}

Cavallo Perin P. ^{[4
]}

Chiariello M. ^{[5
]}

Manzato E. ^{[6
]}

Miccoli R. ^{[7
]}

Modena M.G. ^{[8
]}

Riccardi G. ^{[9
]}

Sesti G. ^{[10
]}

Tiengo A. ^{[11
]}

Trimarco B. ^{[5
]}

Vanuzzo D. ^{[12
]}

Verdecchia P. ^{[13
]}

Zaninelli A. ^{[14
]}

Del Prato S. ^{[15
]}

机构：

[1] Division of Cardiology, University la Sapienza, SantAndrea Hospital, Rome 00189

[2] IRCCS Neuromed, Pozzilli, Isernia

[3] Department of Internal Medicine, University of Bologna, Bologna

[4] Department of Internal Medicine, University of Turin, Turin

[5] Department of Clinical Medicine, Cardiovascular Sciences and Immunology, Naples

[6] Department of Medical and Surgical Sciences, University of Padua, Padua

[7] Department of Endocrinology and Metabolism, University of Pisa, Pisa

[8] Department of Cardiology, University Hospital of Modena, Modena

[9] Division of Endocrinology and Metabolic Disease, University of Naples Federico II, Naples

[10] Department of Clinical and Experimental Medicine, University Magna Graecia of Catanzaro, Catanzaro

[11] Division of Metabolic Diseases, Department of Clinical Medicine, University of Padova, Padova

[12] Centro di Prevenzione Cardiovascolare, ASS4, Udine

[13] Division of Cardiology, Preventive Cardiology Research Unit, S. Maria della Misericordia Hospital, Perugia

[14] University of Florence, Florence

[15] Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, Ospedale Cisanello, Pisa

来源：

High Blood Pressure & Cardiovascular Prevention | 2010年 / 17卷 / 4期

关键词：

abnormal glucose regulation; cardiovascular prevention; diabetes mellitus; hypertension; impaired glucose tolerance; insulin resistance; metabolic syndrome;

D O I：

10.2165/11311990-000000000-00000

中图分类号：

学科分类号：

摘要：

Cardiovascular diseases still represent the leading cause of mortality and hospitalization, worldwide. As a consequence of the marked demographic changes observed in the general population, the improved survival rate after an acute cardiovascular event and the progressive rise of costs (mostly due to technological and pharmacological innovations), the estimated burden of cardiovascular diseases will be soon become insurmountable for national healthcare systems. In this view, an integrated approach aimed at improving strategies for cardiovascular disease prevention and, thus, limiting the negative outcomes, would probably be successful. Such an approach may not only achieve long-term benefits, but even significant advantages in the short to medium term, mostly in asymptomatic high-risk individuals. Indeed, this latter population of asymptomatic high-risk individuals would mostly benefit from extensive application and improvement of strategies for cardiovascular disease prevention with a favourable cost-benefit ratio.The Italian Society for Cardiovascular Disease Prevention Societ Italiana per la Prevenzione Cardiovascolare (SIPREC) has recognized this strategic aim, focusing a significant part of its institutional actions on the effort for providing educational supports and consensus documents, which represent an overview of the scientific knowledge and personal clinical expertise by national and international key opinion leaders. Expert committees periodically generate 'state-of-the-art' documents on specific scientific topics with relevant socioeconomic implications and large clinical impact. The present article is dedicated to healthcare professionals, is based on the available evidence, and provides information on diagnostic algorithms and therapeutic options on abnormal glucose regulation (or dysglycaemia).The relationship between abnormalities in glucose metabolism and cardiovascular complications represents an important and relatively early target for cardiovascular disease prevention. SIPREC identified, even in this clinical setting, a group of scientific experts in order to form a multidisciplinary 'task force'. This group has been asked to explain in a short, simple and effective fashion the epidemiological impact and the pathophysiological nature of the problem, its clinical features, potential diagnostic algorithms and therapeutic options, and its influence on the clinical practice of both specialist physicians and general practitioners.This work provides the background for discussing novel future strategies for cardiovascular prevention. It is also aimed at highlighting the importance of an emerging marker of cardiovascular risk, which is often not recognized and underestimated. © 2010 Adis Data Information BV. All rights reserved.

引用

页码：237 / 247

页数：10

共 33 条

[1]

Volpe M., Borghiccavallo P., Et al., On behalf of the SIPREC Working Group. Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance, High Blood Press Cardiovasc Prev, 17, 2, pp. 73-102, (2010)

[2]

Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data, BMJ, 317, 7155, pp. 371-375, (1998)

[3]

Abdul-Ghani M.A., Tripathy D., DeFronzo R.A., Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose, Diabetes Care, 29, 5, pp. 1130-1139, (2006)

[4]

Gerstein H.C., Santaguida P., Raina P., Morrison K.M., Balion C., Hunt D., Yazdi H., Booker L., Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies, Diabetes Research and Clinical Practice, 78, 3, pp. 305-312, (2007)

[5]

Danaei G., Lawes C.M., Vander Hoorn S., Murray C.J., Ezzati M., Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment, Lancet, 368, 9548, pp. 1651-1659, (2006)

[6]

Bartnik M., Norhammar A., Ryden L., Hyperglycaemia and cardiovascular disease, Journal of Internal Medicine, 262, 2, pp. 145-156, (2007)

[7]

Bianchi C., Miccoli R., Penno G., Et al., Primary prevention of cardiovascular disease in people with dysglycemia, Diabetes Care, 31, SUPPL. 2, (2008)

[8]

Van Den Berghe G., Wilmer A., Hermans G., Meersseman W., Wouters P.J., Milants I., Van Wijngaerden E., Bobbaers H., Bouillon R., Intensive insulin therapy in the medical ICU, New England Journal of Medicine, 354, 5, pp. 449-461, (2006)

[9]

Suleiman M., Hammerman H., Boulos M., Kapeliovich M.R., Suleiman A., Agmon Y., Markiewicz W., Aronson D., Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: A prospective study, Circulation, 111, 6, pp. 754-760, (2005)

[10]

Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., Fonseca V., Gerstein H.C., Grundy S., Nesto R.W., Pignone M.P., Plutzky J., Porte D., Redberg R., Stitzel K.F., Stone N.J., Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association, Circulation, 115, 1, pp. 114-126, (2007)

← 1 2 3 4 →